Larval therapy for leg ulcers (VenUS II): Randomised controlled trial

BMJ (Online)

Volumn 338, Issue 7702, 2009, Pages 1047-1049

  Dumville, Jo C ^e   Worthy, Gill ^a   Bland, J Martin ^a   Cullum, Nicky ^a   Dowson, Christopher ^b   Iglesias, Cynthia ^a   Mitchell, Joanne L ^c   Nelson, E Andrea ^d   Soares, Marta O ^a   Torgerson, David J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c Micropathology Ltd   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMMUNITY HOSPITAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DISEASE DURATION; FEMALE; HUMAN; HYDROGEL; LEG ULCER; MAGGOT THERAPY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; TREATMENT OUTCOME; UNITED KINGDOM; URBAN AREA; VISUAL ANALOG SCALE; WARD; WOUND HEALING;

AGED; ANIMALS; BANDAGES; COST-BENEFIT ANALYSIS; DEBRIDEMENT; DIPTERA; FEMALE; GREAT BRITAIN; HUMANS; HYDROGEL; KAPLAN-MEIER ESTIMATE; LARVA; LEG ULCER; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NECROSIS; PAIN; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 67649097288     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b773     Document Type: Article

References (31)

1. Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg 1994;81:182-187 (Pubitemid 24122342)
2. Cullum N, Nelson EA, Flemming K, Sheldon T. Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy. Health Technol Assess 2001;5:1-221.
3. Cullum N, Nelson EA, Fletcher AW, Sheldon TA. Compression for venous leg ulcers [update of Cochrane Database Syst Rev 2000;(3):CD000265]. Cochrane Database Syst Rev 2001;(2):CD000265.
4. Iglesias C, Nelson EA, Cullum NA, Torgerson DJ, Ven UST. VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers. Health Technol Assess 2004;8:iii. (Pubitemid 39172654)
5. Armstrong DG, Mossel J, Short B, Nixon BP, Knowles EA, Boulton AJM. Maggot debridement therapy: a primer. J Am Podiatr Med Assoc 2002;92:398-401. (Pubitemid 44178793)
6. O'Brien M. Exploring methods of wound debridement. Br J Community Nurs 2002;10-18
7. Sherman RA, Hall MJ, Thomas S. Medicinal maggots: an ancient remedy for some contemporary afflictions. Annu Rev Entomol 2000;45:55-81. (Pubitemid 30187854)
8. Chambers L, Woodrow S, Brown AP, Harris PD, Phillips D, Hall M, et al. Degradation of extracellular matrix components by defined proteinases from the greenbottle larva Lucilia sericata used for the clinical debridement of non-healing wounds. Br J Dermatol 2003;148:14-23. (Pubitemid 36114856)
9. Prete PE. Growth effects of Phaenicia sericata larval extracts on fibroblasts: mechanism for wound healing by maggot therapy. Life Sci 1997;60:505-510 (Pubitemid 27099797)
10. Van der Plas MJA, van der Does AM, Baldry M, Dogterom-Ballering HCM, van Gulpen C, van Dissel JT, et al. Maggot excretions/secretions inhibit multiple neutrophil pro-inflammatory responses. Microbes Infect 2007;9:507-514 (Pubitemid 46436548)
11. Horobin AJ, Shakesheff KM, Pritchard DI. Promotion of human dermal fibroblast migration, matrix remodelling and modification of fibroblast morphology within a novel 3D model by Lucilia sericata larval secretions. J Invest Dermatol 2006;126:1410-1418 (Pubitemid 43997926)
12. Horobin AJ, Shakesheff KM, Pritchard DI. Maggots and wound healing: an investigation of the effects of secretions from Lucilia sericata larvae upon the migration of human dermal fibroblasts over a fibronectin-coated surface. Wound Repair Regen 2005;13:422-433 (Pubitemid 41060424)
13. Bexfield A, Nigam Y, Thomas S, Ratcliffe NA. Detection and partial characterisation of two antibacterial factors from the excretions/secretions of the medicinal maggot Lucilia sericata and their activity against methicillin-resistant Staphylococcus aureus (MRSA). Microbes Infect 2004;6:1297-1304 (Pubitemid 39539727)
14. Huberman L, Gollop N, Mumcuoglu KY, Block C, Galun R. Antibacterial properties of whole body extracts and haemolymph of Lucilia sericata maggots. J Wound Care 2007;16:123-127
15. Huberman L, Gollop N, Mumcuoglu KY, Breuer E, Bhusare SR, Shai Y, et al. Antibacterial substances of low molecular weight isolated from the blowfly, Lucilia sericata. Med Vet Entomol 2007;21:127-131 (Pubitemid 46872707)
16. Thomas S, Andrews AM, Hay NP, Bourgoise S. The anti-microbial activity of maggot secretions: results of a preliminary study. J Tissue Viability 1999;9:127-132
17. Van der Plas MJA, Jukema GN, Wai S-W, Dogterom-Ballering HCM, Lagendijk EL, van Gulpen C, et al. Maggot excretions/secretions are differentially effective against biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother 2008;61:117-122
18. Mumcuoglu KY, Miller J, Mumcuoglu M, Friger M, Tarshis M. Destruction of bacteria in the digestive tract of the maggot of Lucilia sericata (Diptera: Calliphoridae). J Med Entomol 2001;38:161-166 (Pubitemid 33613136)
19. Wayman J, Nirojogi V, Walker A, Sowinski A, Walker MA. The cost effectiveness of larval therapy in venous ulcers. J Tissue Viability 2000;10:91-94
20. Soares MO, Iglesias CP, Bland JM, Cullum N, Dumville JC, Nelson EA, et al. Cost effectiveness analysis of larval therapy for leg ulcers. BMJ 2009;338:b825.
21. Iglesias CP, Birks Y, Nelson EA, Scanlon E, Cullum NA. Quality of life of people with venous leg ulcers: a comparison of the discriminative and responsive characteristics of two generic and a disease specific instruments. Qual Life Res 2005;14:1705-1718 (Pubitemid 40978479)
22. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230-235 (Pubitemid 20045528)
23. Ware JE, Koninski M. SF-36. Physical and mental health summary scores: a manual for users of version 1.2. Lincoln, RI: Quality metric, 2001.
24. Tentolouris N, Petrikkos G, Vallianou N, Zachos C, Daikos GL, Tsapogas P, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. Clin Microbiol Infect 2006;12:186-189 (Pubitemid 43379350)
25. Lecornet E, Robert J, Jacqueminet S, Van Georges H, Jeanne S, Bouilloud F, et al. Preemptive isolation to prevent methicillin-resistant Staphylococcus aureus cross-transmission in diabetic foot. Diabetes Care 2007;30:2341-2342 (Pubitemid 47359044)
26. Richardson M. The benefits of larval therapy in wound care. Nurs Stand 2004;19:70.
27. Sherman R. Age-old therapy gets new approval. Adv Skin Wound Care 2005;18:12-15
28. Sherman RA, Pechter EA. Maggot therapy: a review of the therapeutic applications of fly larvae in human medicine, especially for treating osteomyelitis. Med Vet Entomol 1988;2:225-230
29. Thomas S, Jones M, Shutler S, Jones S. Using larvae in modern wound management. J Wound Care 1996;5:60-69
30. Horn KL, Cobb AH Jr, Gates GA. Maggot therapy for subacute mastoiditis. Arch Otolaryngol 1976;102:377-379
31. Horobin AJ, Shakesheff KM, Woodrow S, Robinson C, Pritchard DI. Maggots and wound healing: an investigation of the effects of secretions from Lucilia sericata larvae upon interactions between human dermal fibroblasts and extracellular matrix components. Br J Dermatol 2003;148:923-933 (Pubitemid 36750784)